PI3K/Akt Signaling in Parkinson's Disease

PI3K/Akt Signaling in Parkinson's Disease

Introduction

The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is a critical pro-survival cascade in dopaminergic neurons, governing cellular energy metabolism, protein homeostasis, mitochondrial function, and resistance to apoptosis. In Parkinson's disease (PD), this pathway intersects with multiple disease-relevant mechanisms including [alpha-synuclein](/proteins/alpha-synuclein) aggregation, mitochondrial dysfunction ([PINK1](/proteins/pink1-protein)/[Parkin](/proteins/parkin)), [LRRK2](/genes/lrrk2) signaling, and neuroinflammation. Understanding PI3K/Akt dysregulation in PD provides insight into disease mechanisms and identifies potential therapeutic targets for neuroprotection. [@yang2022]

PI3K Activation and Membrane Recruitment

Upstream Activators in Dopaminergic Neurons

In the substantia nigra pars compacta (SNc), PI3K/Akt signaling is activated by multiple upstream signals essential for dopaminergic neuron survival: [@sundaram2022]

PI3K/Akt Signaling in Parkinson's Disease

Introduction

The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is a critical pro-survival cascade in dopaminergic neurons, governing cellular energy metabolism, protein homeostasis, mitochondrial function, and resistance to apoptosis. In Parkinson's disease (PD), this pathway intersects with multiple disease-relevant mechanisms including [alpha-synuclein](/proteins/alpha-synuclein) aggregation, mitochondrial dysfunction ([PINK1](/proteins/pink1-protein)/[Parkin](/proteins/parkin)), [LRRK2](/genes/lrrk2) signaling, and neuroinflammation. Understanding PI3K/Akt dysregulation in PD provides insight into disease mechanisms and identifies potential therapeutic targets for neuroprotection. [@yang2022]

PI3K Activation and Membrane Recruitment

Upstream Activators in Dopaminergic Neurons

In the substantia nigra pars compacta (SNc), PI3K/Akt signaling is activated by multiple upstream signals essential for dopaminergic neuron survival: [@sundaram2022]

• Brain-derived neurotrophic factor (BDNF): [BDNF](/proteins/bdnf) binds to [TrkB](/proteins/trkb) receptors, activating PI3K/Akt signaling. BDNF supports dopaminergic neuron survival, and reduced BDNF signaling contributes to PD pathogenesis.
• Glial cell line-derived neurotrophic factor (GDNF): [GDNF](/proteins/gdnf) activates Ret receptor tyrosine kinase, strongly inducing PI3K/Akt signaling. GDNF delivery has been explored in clinical trials for PD neuroprotection.
• Insulin and IGF-1: Insulin receptors and IGF-1 receptors couple to IRS-1/2 and activate PI3K. Brain insulin resistance is increasingly recognized in PD, similar to Alzheimer's disease "type 3 diabetes".
• Dopamine receptor signaling: D1 and D2 dopamine receptors can activate PI3K, creating context-dependent effects on neuronal survival.

PI3K Isoforms in the Brain

Class I PI3Ks relevant to neuronal survival include: [@kwon2024]

| Isoform | Expression | Function in PD | [@cheng2024]
|---------|------------|----------------|
| PI3K p110α (PIK3CA) | Ubiquitous | Growth factor signaling, cell survival |
| PI3K p110β (PIK3CB) | High in brain | GPCR signaling, platelet-derived growth factor |
| PI3K p110δ (PIK3CD) | Immune cells | Neuroinflammation modulation |
| PI3K p110γ (PIK3CG) | Brain, microglia | GPCR signaling, microglial activation |

In dopaminergic neurons, p110α and p110β isoforms are most important for survival signaling, while p110γ in microglia modulates neuroinflammation.

Akt Phosphorylation and Activation

Akt Activation Mechanism

Akt (protein kinase B) requires two phosphorylation events for full activation:

In PD, multiple mechanisms impair Akt activation:

• Reduced PIP3 production: Enhanced PTEN activity or reduced PI3K signaling decreases membrane recruitment of Akt
• PP2A-mediated dephosphorylation: [Alpha-synuclein](/proteins/alpha-synuclein) oligomers activate protein phosphatase 2A (PP2A), which dephosphorylates Akt at both Thr308 and Ser473
• Oxidative stress: Reactive oxygen species can oxidize and inactivate Akt

Akt Substrate Specificity

Akt phosphorylates over 100 substrates, with key targets in PD including:

| Substrate | Site | Effect in PD Context |
|-----------|------|---------------------|
| GSK-3β | Ser9 | Inhibits pro-apoptotic GSK-3β activity |
| mTOR | Ser2448 | Activates mTORC1, regulates autophagy |
| FOXO3a | Ser253 | Promotes nuclear export, blocks pro-apoptotic gene expression |
| BAD | Ser136 | Inhibits BAD-mediated apoptosis |
| ASK1 | Ser83 | Inhibits stress-activated apoptosis |
| Caspase-9 | Ser196 | Direct inhibition of apoptosis |

Downstream Targets in Parkinson's Disease

GSK-3β: The Critical Downstream Effector

[Glycogen synthase kinase-3 beta (GSK-3β)](/proteins/gsk3b) is one of the most important Akt substrates in PD pathogenesis:

• Normal function: Akt phosphorylates GSK-3β at Ser9, inhibiting its activity
• In PD: Reduced Akt activity leads to GSK-3β hyperactivation through diminished Ser9 phosphorylation
• Consequences of GSK-3β activation:
• Enhanced [alpha-synuclein](/proteins/alpha-synuclein) phosphorylation at Ser129, potentially altering aggregation dynamics
• Increased [tau](/proteins/tau) phosphorylation, contributing to comorbid tau pathology
• Activation of mitochondrial apoptosis pathways
• Promotion of neuroinflammation through NF-κB activation

mTOR: Autophagy Paradox

[Akt activates mTORC1](/mechanisms/mtor-neurodegeneration), creating a therapeutic paradox in PD:

• Akt → mTORC1 activation inhibits autophagy, the primary mechanism for clearing [alpha-synuclein](/proteins/alpha-synuclein) aggregates
• mTORC1 inhibition (e.g., with rapamycin) induces autophagy but removes Akt-mediated pro-survival signaling
• Therapeutic implications: This creates a need for strategies that selectively induce autophagy without fully suppressing Akt survival signaling

FOXO Transcription Factors

Akt-mediated phosphorylation of [FOXO3a](/proteins/foxo3a) promotes its nuclear export, preventing transcription of pro-apoptotic genes including:

• Bim (BCL2L11)
• Fas ligand (FASLG)
• PUMA (BBC3)

BAD and Mitochondrial Apoptosis

Unphosphorylated [BAD](/proteins/bad) sequesters anti-apoptotic Bcl-xL, enabling Bax/Bak-mediated mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and caspase activation. Akt phosphorylation of BAD at Ser136 prevents this pro-apoptotic cascade.

PD-Related Alterations in the PI3K/Akt Pathway

LRRK2 Mutations

[LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2) gain-of-function mutations (G2019S, R1441C/G/H) are among the most common genetic causes of familial PD:

• Effect on Akt: LRRK2 G2019S enhances phosphorylation of PTEN, reducing PIP3 levels and Akt activation
• Therapeutic target: LRRK2 inhibitors are in clinical development; their benefit may partly derive from restored Akt signaling

Alpha-Synuclein Pathology

[Alpha-synuclein](/proteins/alpha-synuclein) interacts with PI3K/Akt signaling at multiple points:

• Oligomer toxicity: α-Syn oligomers activate PP2A, dephosphorylating and inactivating Akt
• Akt-mediated phosphorylation: Akt phosphorylates α-syn at Ser129, which may reduce aggregation but the relationship is complex
• Autophagy impairment: α-Syn accumulation inhibits autophagosome-lysosome fusion, compounding mTOR-mediated autophagy suppression

PINK1/Parkin Mitophagy

The [PINK1](/proteins/pink1-protein)/[Parkin](/proteins/parkin) mitophagy pathway is regulated by Akt:

• Akt phosphorylates PINK1: Modulates its kinase activity and stability on damaged mitochondria
• Parkin activation: Akt signaling influences Parkin recruitment and ubiquitination of mitochondrial proteins
• Therapeutic relevance: Enhancing Akt signaling may support mitochondrial quality control

Mitochondrial Dysfunction

PD mitochondria show reduced Akt signaling:

• Complex I deficiency reduces PI3K/Akt activation
• Oxidative stress inactivates Akt
• Reduced mitochondrial biogenesis (via Akt/PGC-1α)

Neuroinflammation

In PD microglia, PI3K/Akt signaling has dual roles:

• Pro-inflammatory: PI3K/Akt in M1 microglia promotes TNF-α, IL-1β, and IL-6 production
• Anti-inflammatory: Akt activation in astrocytes promotes anti-inflammatory phenotype (M2-like)

PI3K/Akt Pathway in PD Models

Neurotoxin Models

MPTP, 6-OHDA, and rotenone models demonstrate:

• Reduced Akt phosphorylation in substantia nigra
• GSK-3β activation following Akt inhibition
• Neuroprotection by Akt activators (e.g., BDNF, GDNF)

Genetic Models

• α-Syn transgenic models: Show impaired Akt signaling
• LRRK2 G2019S knock-in: Exhibits reduced Akt activation
• PINK1 knockout: Enhanced Akt dysregulation under stress

Therapeutic Implications

Akt Activators

| Agent | Mechanism | Clinical Status |
|-------|-----------|-----------------|
| BDNF/TrkB agonists (7,8-DHF) | Direct TrkB activation → PI3K/Akt | Preclinical |
| GDNF delivery | Ret receptor activation | Phase 1/2 trials |
| Intranasal insulin | Insulin receptor → PI3K/Akt | Phase 2 trials |
| PI3K isoform-specific activators | Direct PI3K activation | Preclinical |

Combination Strategies

The PI3K/Akt-mTOR paradox suggests combination approaches:

• Akt activator + mTOR inhibitor: Activate survival signaling while inducing autophagy
• Akt activator + GSK-3β inhibitor: Bypass downstream inhibition
• AMPK activator (metformin): Inhibits mTOR independently of Akt, allowing autophagy without compromising survival

Clinical Trials

Several approaches target PI3K/Akt signaling in PD:

• Exenatide (GLP-1 agonist): Shown in Phase 2 trial to improve motor symptoms, partly through PI3K/Akt signaling
• NL-102 (PAK1 inhibitor): Targets downstream Akt effector, in development
• Inosine: Elevates urate, which may enhance Akt signaling

PI3K/Akt Signaling in PD: Summary Diagram

Cross-Links to Related Pages

Signaling Pathways

• [mTOR Signaling in Neurodegeneration](/mechanisms/mtor-neurodegeneration)
• [GSK3B (Glycogen Synthase Kinase 3 Beta](/proteins/gsk3b)
• [Akt Signaling Pathway](/mechanisms/akt-signaling-pathway)

Parkinson's Disease Mechanisms

• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [PINK1 Protein](/proteins/pink1-protein)
• [Parkin Protein](/proteins/parkin)
• [LRRK2 Gene](/genes/lrrk2)
• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-failure-pd)

Neurotrophic Factors

• [BDNF Protein](/proteins/bdnf)
• [GDNF Protein](/proteins/gdnf)

Therapeutic Approaches

• [Exenatide for Parkinson's Disease](/therapeutics/exenatide-parkinsons-disease)
• [GDNF Therapy for Parkinson's Disease](/therapeutics/gdnf-therapy-parkinsons)
• [mTOR Inhibitors for Neurodegeneration](/therapeutics/mtor-inhibitors)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [PI3K/Akt Signaling in Neurodegeneration](/mechanisms/pi3k-akt-signaling)
• [PI3K Protein](/proteins/pi3k-protein)
• [AKT (Protein Kinase B)](/proteins/akt-protein)

References